Recruiting

Study of Mitazalimab Injection Treatment for Patients with High-Risk Oral Potentially Malignant Disorders

Fast replyInvestigational

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on Oral Potentially Malignant Disorders (OPMD), which are conditions in the mouth that have a risk of becoming cancerous. These conditions include different types of abnormal patches in the mouth such as leucoplakia, erythroplakia, and erythro-leukoplakia. The study will test a new treatment called mitazalimab, which is given as an injection directly into the affected areas of the mouth. This medication works by stimulating the body's immune system to fight against these potentially dangerous mouth conditions.

The main purpose of this study is to determine how effective a short course of mitazalimab treatment is for people with high-risk mouth disorders. During the study, participants will receive the medication through solution for infusion directly into the affected areas of their mouth. The total treatment period will last up to 8 weeks, with specific doses calculated based on body weight.

The study will monitor changes in the mouth conditions over time, particularly focusing on improvements after 6 months of treatment. Participants will need to provide mouth tissue samples and saliva samples throughout the study period. The overall monitoring of participants will continue for several years to track long-term outcomes and any changes in the mouth conditions.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Initial evaluation and diagnosis
Your diagnosis must confirm presence of high risk oral potentially malignant disorder (OPMD), which includes conditions like leucoplakia, erhytroplakia, or erhytro-leukoplakia
The affected area must be at least 2 cm in size
A tissue sample (biopsy) will be taken from your oral cavity for examination
You will need to provide saliva samples for study purposes
Step 2
Treatment administration
You will receive mitazalimab through injection directly into the affected area (intralesional immunotherapy)
The medication will be given as a solution for injection
This will be a short course of treatment
Step 3
6-month evaluation
Your response to treatment will be evaluated after 6 months
This includes examining changes in your condition and tissue samples
You will complete quality of life questionnaires
Additional tissue samples and tests will be conducted to monitor your condition
Step 4
Follow-up period
You will be monitored for up to 3 years
Quality of life assessments will continue every three months for 18 months
Regular examinations will check for any changes in your condition
Additional tissue samples may be taken if needed
Step 5
Final evaluation
The study will assess the long-term effectiveness of the treatment
Final evaluations will include tissue examination and quality of life assessment
The total study duration may extend until January 2030

Who can join the trial?

11 criteria

Must sign a written consent form to participate in the study
Must be at least 18 years old (male or female)
Must have an ECOG Performance Status between 0-2 (a measure of a person's ability to perform daily activities and self-care)
check
Must have a diagnosis of high-risk OPMD (Oral Potentially Malignant Disorder) meeting at least one of these conditions:
- Multiple lesions (2 or more) or connected lesions of 3 cm or larger, or a single lesion 4 cm or larger with tissue changes (dysplasia)
- Lesions present in all four areas of the oral cavity
- At least one lesion with moderate tissue changes
- Lesions with severe tissue changes
- Must have oral lesions that are at least 2 centimeters in size
- Must be willing to undergo oral tissue biopsies for the study
- Must be willing to provide saliva samples
- If previously diagnosed with oral cavity cancer, at least 2 years must have passed since completing treatment

Who cannot join the trial?

13 criteria

History of autoimmune diseases (conditions where the body's immune system attacks its own tissues)
Active or chronic viral infections including hepatitis B, hepatitis C, or HIV
Current or recent treatment with immunosuppressive medications (drugs that reduce immune system activity)
Previous treatment with cancer immunotherapy within the last 6 months
Presence of active oral infections or severe gum disease
History of allergic reactions to similar medications
Pregnant or breastfeeding women
Uncontrolled medical conditions such as diabetes, heart disease, or high blood pressure
Current participation in other clinical trials
Unable to provide informed consent
History of malignant tumors (cancer) in the past 5 years
Significant laboratory test abnormalities
Current systemic corticosteroid treatment (medications like prednisone that affect the whole body)

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Verified
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Palermo, Italy
Verified
Azienda Socio Sanitaria Territoriale Dei Sette Laghi
Varese, Italy
Responsive
Istituto Europeo Di Oncologia S.r.l.
Milan, Italy

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Mitazalimab is an immunotherapy medication that works by stimulating the body's immune system. It is injected directly into the affected areas of the mouth (intralesional injection) to treat potentially pre-cancerous conditions of the oral cavity. This medication aims to help prevent the transformation of high-risk oral lesions into cancerous growths by enhancing the body's natural defense mechanisms.

Mitazalimab

What is already known about the treatment

Mitazalimab - An immunotherapy medication administered through intralesional injection, specifically being studied for the treatment of high-risk oral potentially malignant disorders (OPMD). This monoclonal antibody belongs to the class of immunotherapeutic agents and works by targeting and activating CD40, a protein that plays a crucial role in immune system regulation. The medication is currently in clinical trials to evaluate its effectiveness in preventing the transformation of pre-cancerous oral conditions into malignant lesions, representing a novel approach in oral medicine and preventive oncology.

Investigated diseases

Oral Potentially Malignant Disorder (OPMD) - A group of conditions affecting the mouth's soft tissues that show abnormal changes which may develop into oral cancer. These disorders typically appear as white or red patches in the mouth, particularly on the tongue, inside of cheeks, or lips. The condition can progress gradually, with tissue changes becoming more pronounced over time. Some cases may show varying degrees of cell changes (dysplasia) when examined under a microscope. OPMD can affect multiple areas of the mouth simultaneously and may persist or evolve over months or years.